首页> 外文期刊>Heart >Pulmonary vein isolation combined with substrate modification for persistent atria! fibrillation treatment in patients with valvular heart diseases
【24h】

Pulmonary vein isolation combined with substrate modification for persistent atria! fibrillation treatment in patients with valvular heart diseases

机译:肺静脉隔离结合基质修饰治疗持续性心房!瓣膜性心脏病患者的心律失常治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: To compare the efficacy and safety of pulmonary vein (PV) isolation combined with substrate modification for persistent atrial fibrillation (AF) treatment in patients with and without valvular heart disease (VHD). Methods and results: 111 patients with persistent AF were enrolled for catheter ablation: 51 with valvular heart disease (group I) and 60 without valve defect as controls (group II). Circumferential pulmonary vein isolation (CPVI) and complex fractionated atrial electrogram (CFAE) ablation were performed guided by the CARTO system. The end point was PV isolation and CFAE elimination, which was achieved in almost all patients. There was no significant difference in total procedure time, proportion of PV isolation between two groups. The proportion of AF termination was comparable between the two groups by CPVI, but was higher in group II than in group I by CFAE ablation. The fluoroscopic time was significantly longer in group I than in group II. Temporal catheter entrapment occurred in one patient in group I; one patient in group II developed major stroke. Atrial tachyarrhythmias recurred in 25 (49%) patients of group I and in 27 (45%) of group II at a mean (SD) 4 (2) months of follow-up (p =0.67). Re-ablation was performed in 16 patients of group I and 18 of group II (p = 0.89). At 12 months' follow-up, 34 (66.7%) patients in group I and 43 (71.7%) in group II had no recurrence of atrial tachyarrhythmias (p = 0.56). Conclusion: CPVI combined with CFAE ablation was safe and efficacious for persistent AF treatment in patients with VHD. The outcome was comparable with that in patients without VHD. More x-ray exposure was needed to avoid valve prosthesis impairment.
机译:目的:比较肺静脉(PV)隔离和基质修饰在有或无瓣膜性心脏病(VHD)患者中持续性房颤(AF)治疗的有效性和安全性。方法和结果:111例持续性房颤患者被纳入导管消融术:51例患有瓣膜性心脏病(I组),60例无瓣膜缺损作为对照(II组)。在CARTO系统的指导下进行环周肺静脉隔离(CPVI)和复杂的心房电描记图(CFAE)消融。终点是PV隔离和CFAE消除,几乎所有患者都实现了这一点。两组的总手术时间,PV隔离比例没有显着差异。通过CPVI两组,AF终止的比例相当,但通过CFAE消融,II组高于I组。 I组的透视时间明显长于II组。第一组中有1例患者发生颞管卡住。第二组的一名患者发生了中风。 I组平均25个月(SD)随访4(2)个月,I组25例(49%)和II组27例(45%)复发房性心律失常(p = 0.67)。 I组的16例患者和II组的18例患者进行了再次消融(p = 0.89)。在12个月的随访中,I组34例(66.7%)和II组43例(71.7%)无房性心律失常的复发(P = 0.56)。结论:CPVI联合CFAE消融治疗VHD患者持续房颤是安全有效的。结果与没有VHD的患者相当。需要更多的X射线照射以避免瓣膜假体受损。

著录项

  • 来源
    《Heart》 |2009年第21期|1773-1783|共11页
  • 作者单位

    Department of Cardiology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, No 241 West Huaihai Road, Shanghai,P.R.China 200030;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号